A Look At Xylem (XYL) Valuation After $1b Senior And Blue Notes Financing For Water Projects

Xylem (XYL) has just raised US$1b through senior notes, including 5.200% 2033 notes and 5.450% Blue Notes due 2036, to refinance existing debt and fund water focused sustainability projects.

See our latest analysis for Xylem.

At a share price of US$110.28, Xylem has seen short term share price pressure, with the 30 day return down 9.2% and the year to date share price return down 19.6%. However, the 3 year total shareholder return is up 15.9%, suggesting that recent momentum has faded compared with the longer term picture.

If you are looking beyond Xylem to other infrastructure style opportunities tied to energy and utilities, it may be worth scanning 35 power grid technology and infrastructure stocks

With the stock under pressure in the short term yet still showing a positive 3 year total return, the key question is whether Xylem is now trading below its underlying potential or if the market already reflects its future growth.

Most Popular Narrative: 27.8% Undervalued

The most followed valuation narrative currently pins Xylem's fair value at $152.82, compared with the last close of $110.28, so the story centers on a sizable gap the market has not closed.

Successful post-acquisition integration of Evoqua and revenue synergies from services expansion are accelerating Xylem's shift toward more recurring, higher-margin aftermarket and services revenue streams, boosting earnings stability and long-term profitability.

Read the complete narrative.

Curious what sits behind that confidence in recurring revenue and higher margins? The narrative leans on steady top line growth, rising profitability, and a valuation multiple that assumes investors keep paying a premium for those earnings.

Result: Fair Value of $152.82 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that story can change quickly if government funding for water projects is delayed or if integration of acquisitions such as Evoqua proves tougher than expected.

Find out about the key risks to this Xylem narrative.

Next Steps

Given the mix of confidence and caution so far, this is a good time to review the data yourself and decide whether the optimism feels justified. To see what others are focusing on, take a closer look at the 6 key rewards.

Looking for more investment ideas?

If you stop at just one stock, you risk missing other opportunities that might fit your goals even better, so broaden your search with targeted screeners.

• Spot potential bargains early by checking companies that appear mispriced relative to their fundamentals through the 48 high quality undervalued stocks.
• Prioritize stability and sleep a little easier by reviewing the 69 resilient stocks with low risk scores and seeing which stocks score well on resilience.
• Hunt for future standouts before the crowd catches on by scanning the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com